Morningstar® Investment Profile™   Morningstar®
Disclosure
  Format
for Print
T. Rowe Price Health Sciences Port
Release date as of 2022-05-31. Data on page is subject to change.
Snapshot Ratings & Risk Portfolio Nuts & Bolts
  Morningstar Report
Overall Morningstar
Rating™
What is this?
As of 2022-05-31
Out of 142
Health Funds
Morningstar®
Style Box™
What is this?
As of 2022-03-31
Total Fund Assets ($ Mil)
711.76
View Historical Morningstar Star Ratings and Definitions
  Investment Objective & Strategy  
The investment seeks long-term capital appreciation.
The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.
  Morningstar Category: Health
Health portfolios focus on the medical and health-care industries. Most invest in a range of companies, buying everything from pharmaceutical and medical-device makers to HMOs, hospitals, and nursing homes. A few portfolios concentrate on just one industry segment, such as service providers or biotechnology firms. 
  Investment Risks
Sector Funds: Funds that invest exclusively in one sector or industry involve risks due to the lack of industry diversification and expose the investor to increased industry-specific risks.
  Portfolio Profile
Asset Allocation
% of Net Assets
Bullet U.S. Stocks U.S. Stocks 80.9
Bullet Non-U.S. Stocks Non-U.S. Stocks 9.6
Bullet Bonds Bonds 0.0
Bullet Cash Cash 9.5
Bullet Other Other 0.0
Asset Allocation Rescaled Graph
Data through 2022-03-31
Morningstar Equity Sectors
% of Stocks
Cyclical 1.16
Basic Materials 0.94
Consumer Cyclical 0.00
Financial Services 0.22
Real Estate 0.00
Sensitive 0.00
Communication Services 0.00
Energy 0.00
Industrials 0.00
Technology 0.00
Defensive 98.83
Consumer Defensive 0.00
Healthcare 98.83
Utilities 0.00
Data through 2022-03-31
Holding Status
Total Number of Stock Holdings 182
Total Number of Bond Holdings 0
% of Net Assets in Top 10 Holdings 35.46
Turnover % (as of 2021-12-31) 32.30
30 Day SEC Yield % 0.00
Top Holdings
Sector P/E % of Net
Assets
UnitedHealth Group Inc 27.19 7.83
Thermo Fisher Scientific Inc 29.58 5.07
Danaher Corp 30.96 3.98
Intuitive Surgical Inc 50.70 3.47
Eli Lilly and Co 46.57 3.22
AstraZeneca PLC ADR --- 2.93
Stryker Corp 44.58 2.46
Anthem Inc 20.06 2.33
AbbVie Inc 21.14 2.14
Centene Corp 32.19 2.03
Data through 2022-03-31
  Principal Risks   
Foreign Securities, Loss of Money, Not FDIC Insured, Active Management, Market/Market Volatility, Equity Securities, Industry and Sector Investing, IPO, Other, Restricted/Illiquid Securities, Management, Mid-Cap, Large Cap
Show Risk Definitions
  Other Information
Inception Date: 2000-12-29
Portfolio Manager(s)
Ziad Bakri   (2016-04-01)
Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban
Investment Advisor(s)
T. Rowe Price Associates, Inc.
Issuer
T. Rowe Price
Subadvisor(s)
---
Show Data Definitions

© Copyright 2022 Morningstar, Inc.
All rights reserved. Morningstar, the Morningstar logo, Morningstar.com, Morningstar Tools are either trademark or service marks of Morningstar, Inc. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or any losses arising from any use of information. Past performance is no guarantee of future performance.
Past performance is no guarantee of future results.
Returns will vary and shares may be worth more or less than their original cost when sold.